Moreover, reduced expression of TIMP-3 was found to be a significant prognostic indicator of shortened disease-free survival in the lymph-node-positive and mutant-p53-negative patients, indicating that immunodetection of TIMP-3 protein could improve the prediction of disease recurrence in some subgroups of patients with invasive breast cancer. Here, TP53 is linked to invasive breast carcinoma.